25 Years of Innovation and Excellence: Alma Celebrates Silver Anniversary at the Seventh Alma Academy Event in Thailand
CAESAREA, Israel, Sept. 27, 2024 /PRNewswire/ -- Alma Lasers, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, has announced the global launch of its 25th anniversary celebrations, kicked off at the Alma Academy in Thailand, attended by 340 physicians and company partners from 34 countries. ...
Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer
TAIPEI, Sept. 27, 2024 /PRNewswire/ -- Anbogen, a clinical-stage biotech company, today announced a drug supply collaboration to evaluate the combination of Anbogen's HDAC inhibitor, ABT-301, with BeiGene's anti-PD-1 antibody tislelizumab, in patients with mismatch repair–proficient (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in a global Phase II trial. Under the terms of the agreement, BeiGene will supply...
IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting
SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster presentation of the outcomes of relapsed/refractory multiple myeloma (R/RMM) patients with renal impairment (RI) treated with the fully human anti-BCMA CAR-T cell...
Fresver Beauty Brings Wellness and Beauty Treatment to Buangkok with Their Recent Opening
SINGAPORE, Sept. 27, 2024 /PRNewswire/ -- Fresver Beauty, a renowned leader in beauty and wellness services in Singapore with a rich history dating back to 1988, is excited to announce the grand opening of its new outlet in Buangkok. This relocation from Hougang, where the outlet first opened in 2008, marks a...
LiveWell Awarded Frost & Sullivan’s 2024 Global Customer Value Leadership Award for Advancing Equitable and Accessible Mental Health Solutions
LiveWell's app integrates cutting-edge artificial intelligence (AI) and machine learning to provide personalized mental and behavioral health support, fostering user engagement across 27 countries and 9 languages. SAN ANTONIO, Sept. 27, 2024 /PRNewswire/ -- Frost & Sullivan recently researched the mental and behavioral health industry and, based on its findings, recognizes LiveWell by Zurich (LiveWell) with the 2024 Global...
Datasea Announces Fiscal Year 2024 Financial Results with Revenue 6.6x that of 2023 Primarily due to Growth of its 5G AI Business
The Total Value of 5G-AI Contracts Currently in Process Exceeds $100 MM BEIJING, Sept. 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a Nevada-based digital technology company focused on innovative high-tech intelligent acoustics and 5G AI multimodal digital technology, today announced the Company's financial results for its fiscal year ended June 30, 2024,...
Hong Kong Breast Cancer Registry Report No. 16 Press Conference: Analyze De Novo Metastatic Breast Cancer, Precise Staging Enhances Treatment
HONG KONG, Sept. 26, 2024 /PRNewswire/ -- The Hong Kong Breast Cancer Registry (HKBCR), run by the Hong Kong Breast Cancer Foundation (HKBCF), launched its 16th annual research report today. The report aimed to shed light on the comparison between the patients of de novo metastatic breast cancer (dnMBC) (stage IV) and early breast cancer (eBC) (stages I-II). The...
ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S.
The ZEISS MICOR 700 uses the ZEISS NULEX (non-ultrasonic lens extraction) procedure to help surgeons broaden their intraocular working space, minimizing risk to surrounding eye structures and increasing operating room efficiency. DUBLIN, Calif. and JENA, Germany, Sept. 26, 2024 /PRNewswire/ -- ZEISS Medical Technology today announced the broad U.S. distribution of the...
ArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of therapeutics in respiratory, infectious and pediatric diseases, announced that the results of the phase 3 clinical trial of ziresovir, an oral drug for treatment of respiratory syncytial virus (RSV) infection...
Breakthrough Therapy Designation (BTD) for BioCity’s SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria
SHANGHAI, Sept. 26, 2024 /PRNewswire/ -- BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 has been granted the Breakthrough Therapy Designation (BTD) by National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN) with proteinuria. The BTD for SC0062 was granted based on the outstanding results in subjects with IgAN and proteinuria participating...
